Change in PD-L1 and CD8 Expression after Chemoradiotherapy for Esophageal Squamous Cell Carcinoma

Change in PD-L1 and CD8 Expression after Chemoradiotherapy for Esophageal Squamous Cell Carcinoma

Esophageal cancer has a dismal prognosis with a five-year survival rate below 20%. Recently, immunotherapy has become a new standard of care for this cancer; therefore, we aimed to examine the programmed death ligand 1 (PD-L1) expression in esophageal squamous cell carcinoma (ESCC) tissues before an...

Full description

Bibliographic Details
Main Authors:	Wei-Chung Chen, Chun-Chieh Wu, Yi-Hsun Chen, Jui-Ying Lee, Yao-Kuang Wang, Nian-Siou Wu, Ming-Tsang Wu, I-Chen Wu
Format:	Article
Language:	English
Published:	MDPI AG 2022-08-01
Series:	Biomedicines
Subjects:	esophageal squamous cell carcinoma PD-L1 concurrent chemoradiation therapy CD8 prognosis
Online Access:	https://www.mdpi.com/2227-9059/10/8/1888

Similar Items

Neoadjuvant chemoradiotherapy for thoracic esophageal squamous cell carcinoma: does everyone need it?
by: D. A. Chichevatov, et al.
Published: (2024-05-01)

The efficacy and safety of definitive concurrent chemoradiotherapy for non‐operable esophageal cancer
by: Alexandra D. Dreyfuss, et al.
Published: (2021-02-01)

The Impact of Radiation to Epicardial Adipose Tissue on Prognosis of Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Chemoradiotherapy and Esophagectomy
by: Hung-Chi Tai, et al.
Published: (2021-04-01)

Definitive Chemoradiation with Concurrent Weekly Cisplatin in the Treatment of Esophageal Squamous Cell Carcinoma – A Simplistic Approach
by: Imtiaz Ahmed, et al.
Published: (2021-05-01)

Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma
by: Renxian Xie, et al.
Published: (2024-01-01)

The significance of consolidation chemotherapy after concurrent chemoradiotherapy in esophageal squamous cell carcinoma: a randomized controlled phase III clinical trial
by: Qingshan Zhu, et al.
Published: (2024-10-01)

Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
by: Jiang-Qiong Huang, et al.
Published: (2024-03-01)

Consolidation chemotherapy after definitive concurrent chemoradiotherapy in patients with inoperable esophageal squamous cell carcinoma: a multicenter non-inferiority phase III randomized clinical trial
by: Chengcheng Fan, et al.
Published: (2024-03-01)

YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma
by: Honghai Dai, et al.
Published: (2020-03-01)

The prognostic role of pre-treatment neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy
by: Qirong Man, et al.
Published: (2024-04-01)

Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: a propensity score-matched analysis
by: Chia-Che Wu, et al.
Published: (2018-09-01)

Comparison of therapeutic outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A prospective observational cohort study
by: Yu-Wei Liu, et al.
Published: (2024-01-01)

The Expression of TP63 as a Biomarker of Early Recurrence in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
by: Chih-Hung Lin, et al.
Published: (2024-05-01)

Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, parallel-controlled, phase II clinical trial
by: Ke Zhang, et al.
Published: (2025-02-01)

Predicting response to CCRT for esophageal squamous carcinoma by a radiomics-clinical SHAP model
by: Xu Cheng, et al.
Published: (2023-10-01)

Changes in PD-1 expression on T lymphocyte subsets and related immune indicators before and after definitive chemoradiotherapy for esophageal squamous cell carcinoma
by: Xueling Shi, et al.
Published: (2025-12-01)

Correlation of PD‐L1 expression with CD8+ T cells and oxidative stress‐related molecules NRF2 and NQO1 in esophageal squamous cell carcinoma
by: Xin Zhang, et al.
Published: (2024-07-01)

Long-term results of induction chemotherapy for non-operable esophageal squamous cell carcinoma followed by concurrent chemoradiotherapy: a single-centre experience
by: Xiang Geng, et al.
Published: (2024-09-01)

Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process
by: Anthony M. Brade, et al.
Published: (2024-10-01)

The efficacy and safety of induction chemotherapy combined with sintilimab followed by concurrent chemoradiotherapy plus sintilimab sequencing maintaining with sintilimab for patients with unresectable locally advanced esophageal squamous cell carcinoma
by: Ruifeng Wang, et al.
Published: (2025-01-01)

Case report: Long-term survival in synchronous double primary malignancies of lung adenocarcinomas and esophageal squamous cell carcinoma treated with definitive chemoradiotherapy and SBRT combined with anti-PD-1
by: Rui Zeng, et al.
Published: (2025-02-01)

Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy
by: Xiaolu Ma, et al.
Published: (2022-11-01)

Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma
by: Tianhui Wei, et al.
Published: (2022-04-01)

Successful extirpation of a perforated esophagus after chemo radiotherapy in infiltrative ulcerative squamous cell carcinoma
by: T. S. Rogova, et al.
Published: (2023-06-01)

A retrospective study of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing neutropenia during definitive concurrent chemoradiotherapy in patients with esophageal squamous carcinoma
by: Xin Dong, et al.
Published: (2022-06-01)

Prognosis of Pneumonia in Head and Neck Squamous Cell Carcinoma Patients Who Received Concurrent Chemoradiotherapy
by: Tzu-Hsun Kao, et al.
Published: (2024-07-01)

Efficacy and safety of PD-1 Monoclonal antibodies in the treatment of esophageal squamous cell carcinoma: Systematic review and meta Regression
by: F.A. Ameer, et al.
Published: (2024-07-01)

Perioperative immunotherapy for esophageal squamous cell carcinoma
by: Dan D. Wei, et al.
Published: (2024-02-01)

Chemoimmunotherapy for esophageal squamous cell carcinoma—Summary and discussion of recent clinical trials
by: Zhen Zhang, et al.
Published: (2023-06-01)

Number of Retrieved Lymph Nodes during Esophagectomy Affects the Outcome of Stage III Esophageal Cancer in Patients Having Had Pre-Operative Chemo-Radiation Therapy
by: Wei Ho, et al.
Published: (2024-09-01)

Comparison of the Clinical Outcomes of Esophagectomy and Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma
by: Myung Hun Lee, et al.
Published: (2024-03-01)

Immunotherapy Plus Chemoradiation Improves Overall Survival in Stage IV Esophageal Cancer: A Cohort Study
by: Saber Amin, et al.
Published: (2024-01-01)

Radiotherapy and chemoradiotherapy for postoperative recurrence in patients with esophageal squamous cell carcinoma
by: Qing Liu, et al.
Published: (2024-08-01)

PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis
by: Jia Zhao, et al.
Published: (2023-12-01)

The Impact of Weight Loss during Chemoradiotherapy for Unresectable Esophageal Cancer: Real-World Results
by: Tzu-Ting Huang, et al.
Published: (2022-05-01)

Treatment of cervical esophageal carcinoma: systematic review and meta-analysis
by: D. A. Chichevatov, et al.
Published: (2023-09-01)

Integrated analyses reveal IDO1 as a prognostic biomarker coexpressed with PD-1 on tumor-associated macrophages in esophageal squamous cell carcinoma
by: Yaojun Peng, et al.
Published: (2024-09-01)

Feasibility and Safety of PD-1 Blockades Among Elderly Patients with Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Study
by: Bai M, et al.
Published: (2024-09-01)

Results of combined and chemoradiation treatment of patients with thoracic esophageal cancer according to the data of the regional cancer center
by: E. A. Toneev, et al.
Published: (2023-11-01)

Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy
by: Xiaojie Xia, et al.
Published: (2022-09-01)